About this trial
The UDOPAL Study proposes an innovative home-based care approach for the management of pain in patients admitted to the Home Hospitalization Unit (UHD). This model incorporates interventional pain management techniques into the clinical practice of home-hospital professionals, supported when necessary by specialists from the Pain Medicine Unit.
Pain is a prevalent and often undertreated problem in patients receiving home hospitalization, where complex or oncologic pain may require specialized procedures that traditionally are only performed in hospital settings. The UDOPAL model aims to bridge this gap by providing ultrasound-guided and minimally invasive pain procedures directly at the patient's home, including nerve blocks, infiltrations, and other targeted interventions.
This observational, prospective study evaluates the feasibility, safety, and clinical impact of implementing interventional pain management at home. Adult patients with chronic, oncologic, or complex pain will be included. Outcomes include pain intensity, opioid use, functional improvement, quality of life, and patient satisfaction, as well as adverse events related to the techniques.
The study seeks to provide scientific evidence supporting a new model of interventional home-based pain care that improves comfort, continuity of care, and efficient use of healthcare resources. The project was approved by the Ethics Committee (CEIm Hospital Universitario y Politécnico La Fe, Acta No. 600, 08/10/2025) and is conducted at Hospital de Manises (Valencia, Spain).
Eligibility criteria
Qualifiers
Adult patients (≥18 years old) admitted to the Home Hospitalization Unit (UHD) of the Manises Health Department.
Presence of active pain, classified as mild, moderate, or severe.
Clinical assessment indicating suitability for interventional pain management, as determined by a UDOPAL-trained physician.
Physical and clinical conditions that allow the performance of interventional procedures at home under standardized safety precautions.
Disqualifiers
Very limited life expectancy (estimated survival <72 hours) or terminal/agonal condition.
Uncorrectable coagulopathy.
Systemic infection or local infection at the puncture site.
Documented allergy to any of the planned medications.
Trial design
Treatments tested in this trial
- UDOPAL model